Drug intelligence / Profile preview

INL-003

Development stage: Preclinical
Lead developer: Innocoll
Modality: Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration: Surgical Implant

Overview

**INL-003 (COLLAGUARD)** is a collagen-based surgical barrier film designed to prevent postoperative adhesions. Developed by Innocoll Technologies as a bioresorbable Type I bovine collagen matrix, it acts physically to separate tissue surfaces during the critical healing period, reducing adhesion formation without pharmacological activity. It was intended for use in abdominal and pelvic surgeries prone to adhesions, such as those following herniorrhaphy or laparotomy, with preclinical safety studies completed but no successful advancement to approval noted[10][16][19].

Brand names: COLLAGUARD

Beyond the preview

Go deeper on INL-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INL-003.

Explore the full profile